Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $23.1 million.

  • Axsome Therapeutics' Share-based Compensation rose 666.2% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year increase of 1322.14%. This contributed to the annual value of $85.2 million for FY2024, which is 3608.75% up from last year.
  • Axsome Therapeutics' Share-based Compensation amounted to $23.1 million in Q3 2025, which was up 666.2% from $24.6 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Share-based Compensation registered a high of $24.6 million during Q2 2025, and its lowest value of $9197.0 during Q3 2022.
  • For the 4-year period, Axsome Therapeutics' Share-based Compensation averaged around $15.9 million, with its median value being $18.9 million (2023).
  • In the last 5 years, Axsome Therapeutics' Share-based Compensation skyrocketed by 17787107.75% in 2023 and then skyrocketed by 666.2% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Share-based Compensation (Quarter) stood at $10.8 million in 2022, then skyrocketed by 75.66% to $18.9 million in 2023, then rose by 16.24% to $22.0 million in 2024, then rose by 5.08% to $23.1 million in 2025.
  • Its last three reported values are $23.1 million in Q3 2025, $24.6 million for Q2 2025, and $23.3 million during Q1 2025.